加载中...

MedXY News - oncology

MedXY AI/MedXY News/Tag: oncology

MedXY News

EnglishTag

oncology

78 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit

Section: newsFeb 19, 2026

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i

Section: Hematology-OncologyFeb 19, 2026

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients

A qualitative study published in JAMA Network Open identifies how limited cultural capital, cancer-related stigma, and economic deprivation form a self-reinforcing cycle that excludes low-income patients from hospice care, highlighting the

Section: newsFeb 11, 2026

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d

Section: newsFeb 10, 2026

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser

Section: newsFeb 10, 2026

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity

A multisite study reveals that financial toxicity significantly reduces life satisfaction in cancer patients. However, hopefulness and social support act as critical mediators, suggesting that integrating psychosocial resilience training wi

Section: newsFeb 10, 2026

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

A population-based cohort study using SEER-21 data reveals that patients diagnosed with cancer during 2020 and 2021 experienced significantly lower 1-year cause-specific survival rates compared to prepandemic trends, resulting in an estimat

Section: newsFeb 10, 2026

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological out

Section: newsFeb 8, 2026

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin

Section: newsFeb 6, 2026

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.

Section: Diabetes & EndocrinologyFeb 5, 2026

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma

This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra

Section: newsJan 31, 2026

Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms

Low-Dose Aspirin and Cancer Mortality in Older Adults: Long-Term ASPREE Results Challenge Previous Paradigms

A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin’s

Section: Internal MedicineJan 30, 2026

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a

Section: newsJan 29, 2026

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-year

Section: General SurgeryJan 25, 2026

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.

Section: newsJan 25, 2026

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncolo

Section: newsJan 20, 2026

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to

Section: newsJan 20, 2026

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Section: newsJan 19, 2026

Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry

Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry

This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.

Section: GastroenterologyJan 15, 2026

$Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors$

Breaking Resistance: SBRT Plus Cadonilimab Shows Promising Efficacy in Heavily Pretreated Refractory Solid Tumors

A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi

Section: newsJan 14, 2026

Prev 1 2 3 4 Next